Litcius/Paper detail

Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?

Marianne de Brito, Zenas Z N Yiu

2021American Journal of Clinical Dermatology22 citationsDOI

Topics & Concepts

UstekinumabMedicinePsoriasisInterleukin 23Observational studyRandomized controlled trialInternal medicineDiseaseSecukinumabDermatologyInterleukinPsoriatic arthritisAdalimumabCytokinePsoriasis: Treatment and PathogenesisCytokine Signaling Pathways and InteractionsDermatology and Skin Diseases
Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say? | Litcius